Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
97.44 USD | -1.64% | +3.26% | -3.50% |
Apr. 26 | NOVARTIS AG : Receives a Buy rating from Jefferies | ZD |
Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
Financials (USD)
Sales 2024 * | 48.78B | Sales 2025 * | 50.62B | Capitalization | 200B |
---|---|---|---|---|---|
Net income 2024 * | 10.37B | Net income 2025 * | 11.9B | EV / Sales 2024 * | 4.35 x |
Net Debt 2024 * | 12.65B | Net Debt 2025 * | 11.18B | EV / Sales 2025 * | 4.17 x |
P/E ratio 2024 * |
19.4
x | P/E ratio 2025 * |
16.7
x | Employees | 76,057 |
Yield 2024 * |
3.69% | Yield 2025 * |
3.82% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 day | -1.64% | ||
1 week | +3.26% | ||
Current month | +0.73% | ||
1 month | +2.28% | ||
3 months | -9.07% | ||
6 months | +3.33% | ||
Current year | -3.50% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
8.01% | 13 M€ | -.--% | ||
1.52% | 9 M€ | -4.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 97.44 | -1.64% | 1,562,845 |
24-04-25 | 99.06 | +0.72% | 2,421,300 |
24-04-24 | 98.35 | +1.10% | 2,472,990 |
24-04-23 | 97.28 | +2.27% | 3,837,430 |
24-04-22 | 95.12 | +0.81% | 2,447,775 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
-9.61% | 195B | |
-6.26% | 145B | |
-11.77% | 144B |
- Stock Market
- Equities
- NOVN Stock
- NVS Stock